Vectus Biosystems (ASX:VBS) Receipts from Customers : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Receipts from Customers?

Vectus Biosystems's Receipts from Customers for the six months ended in Dec. 2024 was A$0.00 Mil.

Vectus Biosystems's Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Vectus Biosystems Receipts from Customers Historical Data

The historical data trend for Vectus Biosystems's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Receipts from Customers Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Receipts from Customers

Get a 7-Day Free Trial

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Receipts from Customers	Get a 7-Day Free Trial													-	-	-	-	-

Vectus Biosystems Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Vectus Biosystems Receipts from Customers Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Receipts from Customers provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Receipts from Customers

Comparable Companies

Traded in Other Exchanges

N/A

Address

26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines